Mavacamten for HCM

(16:29)

ACC: Mavacamten For Hypertrophic Cardiomyopathy

(5:12)

The EXPLORER-HCM study: mavacamten for obstructive HCM

(1:38)

2024 Guideline for the Management of Hypertrophic Cardiomyopathy

(16:58)

ICER CTAF Public Meeting on Mavacamten for Hypertrophic Cardiomyopathy - Evidence Presentation

(1:45:31)

AHA 24: VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy

(10:31)

Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows

(1:52)

Breakthrough therapy designation for Mavacamten in HOCM

(3:13)

AHA 24: Mavacamten: Real-World Experience from 22 Months of the REMS Program

(7:20)

ICER CTAF Public Meeting on Mavacamten for Hypertrophic Cardiomyopathy - Policy Roundtable

(1:51:)

New Treatment Option for Hypertrophic Cardiomyopathy | Mavacamten

(5:37)

ICER CTAF Public Meeting on Mavacamten for Hypertrophic Cardiomyopathy - Voting Session

(52:15)

ICER CTAF Public Meeting on Mavacamten for Hypertrophic Cardiomyopathy - Public Comments

(39:17)

Hypertrophic cardiomyopathy guideline update: Mayo Clinic's perspective

(12:28)

Clinical Trial Shows Drug is Effective in Nearly 80% of Patients with Hypertrophic Cardiomyopathy

(2:10)

Safety and Efficacy of Mavacamten in Symptomatic Non-Obstructive HCM: The MAVERICK-HCM Study

(1:58)

MedTap: Mavacamten side effects

(2:35)

Health check: 'Promising results' for heart drug

(53)